The Food and Drug Administration (FDA) has approved Myqorzo™ (aficamten) for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and ...

MYQORZO, a Cardiac Myosin Inhibitor, Directly Addresses Underlying Hypercontractility Associated with Obstructive HCM ...

Introduction More than 75% of the global population resides in low- and middle-income countries (LMICs), where ...

After 27 years in business, Cytokinetics hopes to pit its own cardiac myosin inhibitor against one it initially developed—now owned by Bristol Myers Squibb—in a market worth billions. Aficamten has a ...

The US Food and Drug Administration has approved aficamten (Myqorzo), an allosteric cardiac myosin inhibitor, for adults with ...

Final Decision from European Commission Expected in Q1 2026SOUTH SAN FRANCISCO, Calif., (GLOBE NEWSWIRE) -- Cytokinetics, ...

The clearance is the first in Cytokinetics’ lengthy history and pits its drug Myqorzo against Bristol Myers’ Camzyos, which ...

Everything you need to know about ATV upcoming drama series ABİ."ABİ – Aile Bir İmtihandır" is a new show that many people ...

Many of the tactics used by modern militaries were forged long before today’s conflicts ever began. During the Cold War, ...

Marines deploy with a variety of weapons, but only a handful consistently earn their confidence in real-world conditions. From salty sea air aboard ship to sand-filled valleys in the Middle East, ...